Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma

Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma

Background. Pancreatic ductal adenocarcinoma (PDAC) displays a typical mucin expression pattern which is characterized by MUC1 positive, MUC2 negative, and MUC5AC positive. More and more evidences show that mucins are involved in the development of pancreatic diseases. However, the relationship betw...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yunzhen Qian, Yitao Gong, Yu Liu, Yusheng Chen, Ruijie Wang, Zhengjie Dai, Xuan Zou, Yesiboli Tasiheng, Guopei Luo, Xuan Lin, Xu Wang, He Cheng, Xianjun Yu, Chen Liu
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Series:	Journal of Immunology Research
Online Access:	http://dx.doi.org/10.1155/2022/7353572
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Primary Mucinous Adenocarcinoma of the Testis
by: Takeshi Azuma, et al.
Published: (2012-01-01)

Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
by: Heng‐Chung Kung, et al.
Published: (2023-04-01)

Clinical Outcome Differences in Mucinous Versus Non-Mucinous Colonic Adenocarcinoma: A Comparative Study
by: Adrian Cote, et al.
Published: (2025-01-01)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
by: Edgar Linden-Castro, et al.
Published: (2014-01-01)

Mucin-producing urothelial-type adenocarcinoma of the prostate with a gene mutation characteristic of intestinal adenocarcinoma: case report and literature review
by: Ao Yu, et al.
Published: (2025-01-01)

Patients with colorectal cancer combined with HIV had a worse overall survival after surgery: a meta-analysis
by: Wen-Wen Yang, et al.
Published: (2025-01-01)

Prognostic significance of ımmunhistochemical axl expression in pancreas ductal adenocarcinomas
by: Ozden Oz, et al.
Published: (2023-07-01)

Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma
by: Caroline Y. K. Fong, et al.
Published: (2019-01-01)

Mucinous rectal adenocarcinoma recurrence: A case report and literature review
by: Riya Sood, BS, et al.
Published: (2025-04-01)

Multiphoton imaging-based quantifiable collagen signatures for predicting outcomes in patients with pancreatic ductal adenocarcinoma
by: Xiwen Chen, et al.
Published: (2025-02-01)

Proximal bronchiolar adenoma with malignant transformation to invasive mucinous adenocarcinoma with 4 years follow-up: a case report and literature review
by: Yuan-Hui Yang, et al.
Published: (2025-01-01)

DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma
by: Jianyu Yang, et al.
Published: (2019-01-01)

Identification of key regulators in pancreatic ductal adenocarcinoma using network theoretical approach.
by: Kankana Bhattacharjee, et al.
Published: (2025-01-01)

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
by: Muhammad Shahid Iqbal, et al.
Published: (2014-01-01)

A Morphological and Immunohistochemical Study of the Tumoral and Inflammatory Cells in Pancreatic Ductal Adenocarcinoma
by: Vlad Herlea, et al.
Published: (2020-01-01)

Nuclear Position and Shape Deformation of Chromosome 8 Territories in Pancreatic Ductal Adenocarcinoma
by: Sylvia Timme, et al.
Published: (2011-01-01)

Urachal Mucinous Cystic Tumor of Low Malignant Potential with Concurrent Sigmoid Colon Adenocarcinoma
by: Kelly Brennan, et al.
Published: (2019-01-01)

Six MicroRNA Prognostic Models for Overall Survival of Lung Adenocarcinoma
by: Juan Li, et al.
Published: (2022-01-01)

Mucin-Poor Mucinous Tubular and Spindle Cell Carcinoma of the Kidney Presented with Multiple Metastases Two Years after Nephrectomy: An Atypical Behaviour of a Rare, Indolent Tumour
by: I. Sokolakis, et al.
Published: (2017-01-01)

Novel Pt (II) Complexes With Anticancer Activity Against Pancreatic Ductal Adenocarcinoma Cells
by: Erika Stefàno, et al.
Published: (2024-01-01)

Lymphopenia Is Associated with Gross Target Volumes and Fractions in Hepatocellular Carcinoma Patients Treated with External Beam Radiation Therapy and Also Indicates Worse Overall Survival
by: Hai-Ge Zhang, et al.
Published: (2019-01-01)

Mucinous Adenocarcinoma Arising in Chronic Perianal Fistula: Good Results with Neoadjuvant Chemoradiotherapy Followed by Surgery
by: Marisa D. Santos, et al.
Published: (2014-01-01)

Annexin A2 Expression in the Aerogenous Spread of Pulmonary Invasive Mucinous Adenocarcinoma with Gastric Lineage
by: Kazumori Arai, et al.
Published: (2020-01-01)

A Case of Large Perianal Mucinous Adenocarcinoma Arising from Recurrent Abscess and Complex Fistulae
by: Fahmi Pramaditto Azmi, et al.
Published: (2020-01-01)

Development and characterization of orthotopic patient-derived xenograft models of peritoneal metastatic mucinous appendiceal adenocarcinoma
by: I. Ito, et al.
Published: (2025-03-01)

The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma
by: Prachi Bhatt, et al.
Published: (2024-12-01)

Elevated SAMD3 expression in T cells predicts improved survival in pancreatic ductal adenocarcinoma patients
by: Lingyi Fu, et al.
Published: (2025-02-01)

Identification and validation of a novel autoantibody biomarker panel for differential diagnosis of pancreatic ductal adenocarcinoma
by: Metoboroghene O. Mowoe, et al.
Published: (2025-01-01)

It’s about TIME – Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma
by: Christin Knickmeier, et al.
Published: (2025-01-01)

Surgical Outcomes Following Neoadjuvant Treatment for Locally Advanced and Borderline Resectable Pancreatic Ductal Adenocarcinoma
by: Kai Tai Derek Yeung, PhD, FRCS, et al.
Published: (2024-09-01)

TIM‐4 increases the proportion of CD4+CD25+FOXP3+ regulatory T cells in the pancreatic ductal adenocarcinoma microenvironment by inhibiting IL‐6 secretion
by: Ziyao Wang, et al.
Published: (2024-09-01)

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
by: Li Zhang, et al.
Published: (2023-01-01)

Pseudomyxoma Peritonei Originating from Transverse Colon Mucinous Adenocarcinoma: A Case Report and Literature Review
by: Yingbo Gong, et al.
Published: (2020-01-01)

Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell‐free RNA
by: Martin Metzenmacher, et al.
Published: (2025-02-01)

Assessing the diagnostic potential of SATB2 and β-catenin as biomarkers and therapeutic targets in pancreatic ductal adenocarcinoma
by: Noha Said Helal, et al.
Published: (2025-01-01)

Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma
by: Takeshi Terashima, et al.
Published: (2025-01-01)

Improved Predictability of Diagnosis and Prognosis Using Serum‐ and Tissue‐Derived Extracellular Vesicles From Bulk mRNA Sequencing in Pancreatic Ductal Adenocarcinoma
by: Qian Zhu, et al.
Published: (2025-01-01)

A Giant Mucinous Adenocarcinoma Arising within a Villous Adenoma of the Urachus: Case Report and Review of the Literature
by: Steven Joniau, et al.
Published: (2009-01-01)

Atypical Presentation of Skull Metastasis from Rectal Adenocarcinoma as an Initial Symptom of Recurrence
by: Cemal Fırat, et al.
Published: (2012-01-01)

Multiomic quantification of the KRAS mutation dosage improves the preoperative prediction of survival and recurrence in patients with pancreatic ductal adenocarcinoma
by: Won-Gun Yun, et al.
Published: (2025-01-01)